ampakines

ampakines

A class of drugs that act on nerve cell receptors to make them more responsive to the NEUROTRANSMITTER glutamate. Ampakines alter the ways in which a memory is encoded and modify the strength of the memory trace. A few small clinical trials have suggested that ampakines can significantly improve memory in elderly people. The duration of action is short.
References in periodicals archive ?
The nootropic segment by types is further segmented into racetams, ampakines, choline & acetylcholine intermediates, others.
Ampakines. The second platform of proprietary medicines being developed by RespireRx are ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors.
In that regard, ampakines are experimental drugs that have been shown to improve opioid-induced ventilation without loss of the analgesic effect (Clin Pharmacol Ther.
[2] Some various drug groups that are approved by the US Food and Drug Administration are racetam, cholinergics, acetylcholinesterase inhibitors, AMPAkines, smart drugs, dopaminergics, nootropic vitamins, and neurohormones.
May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 70
The team, led by Lynch, Julie Lauterborn, and Linda Palmer, wanted to know whether dendritic retraction was already underway in 13-month-old or "middle-aged" rats and, if it was, could they reverse it by giving rats a compound called an ampakine. Ampakines had previously been shown to improve age-related cognitive deficits in rats as well as increase production of a key growth factor, brain-derived neurotrophic factor (BDNF) in the brain.
Cortex Pharmaceuticals added that the proceeds may be used to support its clinical development of ampakines for the treatment of central sleep apnea and opiate induced respiratory depression, commencing with a Phase 2A clinical study of CX1739, the lead ampakine, as well as to fund corporate general and administrative costs.
Gall, "Ampakines and the Threefold Path to Cognitive Enhancement," Trends in Neuroscience 29 (2006): 554-62.
Ampakines, a new class of drugs developed by Lynch, are currently in clinical development for Alzheimer's disease and attention-deficit hyperactivity disorder (ADHD).
Studies of cells in the laboratory have shown that drugs called ampakines elevate production of BDNF.
Scientists in California are developing a class of experimental drugs call ampakines which flood the brain with a neurotransmitter that makes learning easy, improves memory and boosts alertness.